Table 1 Baseline characteristics of subjects in the 2 groups

Age (years)

56.8 ± 12.3

56.3 ± 12.4

Sex (Male/Female)

15/14

13/14

Body weight (kg)

66.2 ± 16.3

67.2 ± 15.9

BMI (kg/m²)

25.2 ± 3.6

25.4 ± 3.7

Waist Circumference (cm)

93.55 ± 10.5

93.46 ± 10.4

duration of diabetes (years)

15.6 ± 5.7

15.4 ± 6.2

Hypertention (+/−)

22/7

21/6

Retinopathy(NDR/SDR/PDR)

2/17/10

2/16/9

Nephropathy(Normo-/micro-/macroalbuminuria)

6/14/9

5/14/8

CVD(−/+)

5/24

5/22

α-glucosidase inhibitors(-/ +)

2/27

1/26

Metformin (−/ +)

13/16

14/13

Duration of insulin treatment (years)

9.6 ± 3.4

9.4 ± 3.5

Total insulin dose (unit/day)

68.6 ± 14.6

66.8 ± 13.9

Frequency of insulin injection (2-/3−/−4 times /d)

17/8/4

16/7/4

HbA1c (%)

9.3 ± 1.5

9.4 ± 1.4

FBG (mmol/L)

11.4 ± 2.4

11.3 ± 2.6

P2BG (mmol/L)

16.8 ± 4.4

17.0 ± 4.5

Triglyceride (mmol/L)

3.26 ± 1.14

3.28 ± 1.16

Total Cholesterol (mmol/L)

6.23 ± 1.41

6.19 ± 1.51

HDL-Cholesterol (mmol/L)

1.04 ± 0.23

1.12 ± 0.21

LDL-Cholesterol (mmol/L)

4.13 ± 1.01

4.20 ± 1.02

Serum C peptide (ng/ml)

1.06 ± 0.68

1.06 ± 0.70

HMW adiponectin (μg/ml)

3.12 ± 1.56

3.22 ± 1.54